Xenon Pharmaceuticals Inc (XENE) - Multiplikator Forward P/S

Logo grafis Xenon Pharmaceuticals Inc (XENE)

Xenon Pharmaceuticals (XENE) management is awaiting the results of final-stage trials for new molecules, with R&D costs already priced in. The forward P/S of the business on GURU.Markets demonstrates the results of this strategy, where 710.90 shows the current value of the metric. The model relies on outsourced production and logistics, while strong pricing power in the epilepsy segment will ensure precise revenue from the unique therapy.

XENE Xenon: Rega forward marang dodolan ing interval 04.07.2022 - 08.05.2026

Rincian metrik lan analitis perusahaan Xenon Pharmaceuticals (XENE)

Analisis kabeh metrik perusahaan:xenon-pharma.com XENE
Sampel barang Xenon Corp

To find a balance between cost and business quality, use the ratio of current market capitalization to expected revenue, which determines the extent of the overpayment for future sales growth. In GURU.Markets, the forward P/S ratio trend reflects market confidence in the management discipline of Xenon Pharmaceuticals (XENE) regarding the execution of clinical plans for its neurological portfolio, allowing for an assessment of whether the premium for the issuer's potential is justified.

Analisis pesaing

Multiplikator Forward P/S BIIB (Biogen Idec)|Rasio kapitalisasi marang dodolan sing dikarepake Neurocrine Corp (NBIX)|RGC: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan AXSM (Axsome Therapeutics)|ACAD: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Viking Therapeutics Inc (VKTX)|SUPN (Supernus Pharma) - Multiplikator Forward P/S|CPRX: Rega forward marang dodolan|Multiplikator Forward P/S DNLI|Rasio kapitalisasi marang dodolan sing dikarepake Harmony Biosciences|Biohaven Ltd - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S Amylyx Pharmaceuticals, Inc. AMLX|TRVI: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Praxis Corp PRAX|AVXL: Multiplikator Forward P/S|CBLL (ceribell.com) - Rasio rega marang prakiraan pendapatan|PRTA (Prothena Corporation) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan alector.com (ALEC)|Rasio rega marang prakiraan pendapatan Annexon, Inc. (ANNX)|OMER - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S NGNE (Neurogene Inc)|AC Immune (ACIU) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Voyager Therapeutics Inc - Multiplikator Forward P/S|Neumora (NMRA) - Multiplikator forward rega marang pendapatan|SCLX: Multiplikator Forward P/S|TVGN - Rasio kapitalisasi marang dodolan sing dikarepake|ACOG (Alpha Cognition Inc) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan cogrx.com (CGTX)|Rasio rega marang prakiraan pendapatan Inhibikase Therapeutics Inc (IKT)|Rasio kapitalisasi marang dodolan sing dikarepake Cassava Sciences|Multiplikator Forward P/S ASRT (Assertio Holdings)|COYA - Multiplikator forward rega marang pendapatan|vistagen.com - Multiplikator Forward P/S|OVID: Rasio rega marang prakiraan pendapatan|Acumen Pharmaceuticals, Inc (ABOS) - Rasio rega marang prakiraan pendapatan|CervoMed Inc - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Alterity Therapeutics Limited|clene.com (CLNN) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan PEPG (PepGen Inc)|Multiplikator Forward P/S jupiterneurosciences.com (JUNS)|Rasio rega marang prakiraan pendapatan Relmada Therapeutics, Inc. RLMD|ANVS: Kapitalisasi marang prakiraan pendapatan|Grace Tx - Multiplikator Forward P/S|AIFF (Firefly Neuroscience Inc) - Kapitalisasi marang prakiraan pendapatan|KLTO: Multiplikator Forward P/S|NeuroSense Therapeutics, Ltd. (NRSN) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Reviva Pharmaceuticals, Inc.|Multiplikator forward rega marang pendapatan metaviatx.com (MTVA)|Multiplikator Forward P/S NRXS|HSDT - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Passage Bio, Inc. - Multiplikator forward rega marang pendapatan|bionomics.com.au (NEUP) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Minerva - Multiplikator Forward P/S|Rega forward marang dodolan ATHA (Athira Pharma Inc)|ADXN: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan ALZN|CYCN (Cyclerion Therapeutics Inc.) - Multiplikator Forward P/S|PTIX (Protagenic Therapeutics) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S KTTA|Rasio kapitalisasi marang dodolan sing dikarepake Cortigent|Multiplikator Forward P/S ATXI (avenuetx.com)|BrainStorm Cell Therapeutics Inc. - Rasio rega marang prakiraan pendapatan|Cara Therapeutics Inc. - Multiplikator Forward P/S|Chromocell Therapeutics (CHRO) - Multiplikator forward rega marang pendapatan|ELYM: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Intra-Cellular Therapies Inc.|LBPH (Longboard Pharmaceuticals Inc) - Multiplikator Forward P/S|Marinus - Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S NKGN|NRBO (NeuroBo Pharmaceuticals) - Rega forward marang dodolan|Multiplikator Forward P/S SAGE (Sage Therapeutics Inc)|Rasio kapitalisasi marang dodolan sing dikarepake Synaptogenix Inc. (SNPX)|TRVN - Rasio rega marang prakiraan pendapatan|vigilneuro.com (VIGL) - Multiplikator forward rega marang pendapatan|WENA: Multiplikator Forward P/S|Cerevel Therapeutics, Inc. (CERE) - Multiplikator Forward P/S